Navigation Links
Imagenetix, Inc. Reports Second Quarter and Six Month Results
Date:11/12/2008

- Second Quarter Revenue Increases by 45% From Prior Year

- Second Quarter After Tax Income of $199,000

- Six Month Revenue Increases by 37% From Prior Year

- Six Month After Tax Income of $786,000

SAN DIEGO, Nov. 12 /PRNewswire-FirstCall/ -- Imagenetix, Inc. (OTC Bulletin Board: IAGX) announced today results for its second fiscal quarter and six month period ending September 30, 2008. Net sales for the quarter were $2,656,000 an increase of 45% from the $1,829,000 reported for the same period of the prior fiscal year and up 91% sequentially from revenue of $1,344,000 in the first fiscal 2009 quarter. For the six month period, net sales increased by 37% to $4,051,000 from $2,956,000 as was reported in the prior six month period.

After tax income for the second quarter increased to $199,000, $.02 per share, from the loss of ($631,000), ($.06) per share, during the same quarter of the prior fiscal year. For the six month period after tax income increased to $786,000, $.07 per share, compared to the loss of ($1,066,000), ($.10) per share, in the previous six month period. First quarter results included a one-time litigation settlement.

Commenting on the results for the quarter, Mr. William P. Spencer, Imagenetix's Chief Executive Officer said, "We have begun making progress in selling our Inflame Away-Celadrin(R) joint health formulas through mass market stores. We have advanced Celadrin through an in-store warehouse club test. Also, we have added distribution of Inflame Away-Celadrin through the #1 national supermarket retail chain this past quarter. With greater expansion and success in the supermarket and warehouse club segments of the mass market, our company would continue to see both increased revenues and improved gross profit margins which would translate into enhanced bottom line performance."

Imagenetix, based in San Diego, California, is an innovator of scientifically
'/>"/>

SOURCE Imagenetix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
2. China-Biotics, Inc. Reports Second Quarter 2009 Financial Results
3. Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units
4. Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year
5. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
6. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
7. BMP Sunstone Reports Third Quarter 2008 Financial Results
8. Endocare Reports Financial Results for Third Quarter 2008
9. Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs
10. Isis Reports Financial Results and Highlights for Third Quarter of 2008
11. OncoGenex Reports Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Bedford, NH (PRWEB) , ... July 30, 2015 ... ... efficiency homogenizer for advanced fluid applications and designed for continuous operation up to ... clean-in-place and sterilization-in-place, ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ ...
(Date:7/29/2015)... July 29, 2015 US-Australian drug discovery company, ... confirmed it is committed to progressing its ground-breaking technology ... practicable and to ensure the Company delivers the best ... Iain Ross , said the Company currently had ... pre-clinical programs, discovery programs and academic partnerships and initiatives, ...
(Date:7/29/2015)... , July 29, 2015  AsureQuality and Ubiquitome ... testing for applications in food and primary production ... powered real-time PCR device, the Freedom4. ... through to the supermarket shelf for producers, processors ... involvement in animal disease control and pest management ...
(Date:7/29/2015)... -- AmnioChor Inc., an early stage biotech startup based on ... that the Musculoskeletal Transplant Foundation of Edison ... seed round of development of the proprietary AmnioCept™ product ... AmnioChor,s technology allows cryopreservation of the amniotic membrane ... within those tissues. Amnion is a well-established source of ...
Breaking Biology Technology:GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2
... ISIS ) announces the following webcast: , , ... of a, microRNA, ... 1, 2008, at 8:30 a.m. ET / 5:30 a.m. PT, Where: ... Simply log onto our website listed above., , ...
... in the research of vein treatment methods led by Dr. Sinjae Hyun, ... new medical device, which he will present this summer to his research ... ... A gift from a California company aided in the research of ...
... Dec. 1 Cell Therapeutics, Inc. (CTI),(Nasdaq and ... and Drug,Administration (FDA) has accepted for filing and ... supplemental Biologics License Application,(sBLA) for use of Zevalin(R) ... B-cell non-Hodgkin,s lymphoma who achieve,a response to first-line ...
Cached Biology Technology:Gift Aids Professor's Research into Vein Treatment 2Gift Aids Professor's Research into Vein Treatment 3Gift Aids Professor's Research into Vein Treatment 4FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review 2FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review 3FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review 4FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review 5
(Date:7/27/2015)... 27, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Huawei has selected the Synaptics ... its stylish smartwatch. Huawei chose the state-of-the-art ClearPad ... power and highly responsive human interface qualities such ... also required a classic round watch face and ...
(Date:7/23/2015)... Mass., July 23, 2015 Aware, Inc. (NASDAQ: ... today reported financial results for its second quarter ended June ... of 2015 was $4.5 million, a decrease of 33% compared ... income in the second quarter of 2015 was $0.3 million, ... or $0.04 per diluted share, in the same period a ...
(Date:7/21/2015)... , July 21, 2015 Today, ZTE announced ... received as well as expected revenues in 2015 that relate to ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ... a leading smartphone manufacturer in China and ... 02 5 for Axon , ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2
... search for better ways to target anticancer drugs to ... nanoparticles called buckyballs might be used to significantly boost ... In research due to appear in an upcoming issue ... and The University of Texas M. D. Anderson Cancer ...
... the National Institute of Standards and Technology (NIST) have ... for small numbers of biomolecules. The unusually simple containment ... and perhaps lead to the development of molecule-sorting devices ... research. The work was reported in the July 3 ...
... world soon could be made completely flood-tolerant because ... in collaboration with scientists at UC Davis and ... By gradually introducing into California rice "submergence tolerance," ... flood conditions, the researchers show how potentially any ...
Cached Biology News:Buckyballs boost antibody's chemotherapy payload 2'Micro-boxes' of water used to study single molecules 2Researchers develop flood-tolerant California rice 2Researchers develop flood-tolerant California rice 3
... The potential applications for the use of ... gene expression via the RNA interference (RNAi) ... cellular and molecular biology fields. siRNA for ... either chemically or enzymatically, and then transfected ...
... applications for the use of small interfering ... via the RNA interference,(RNAi) pathway have generated ... biology fields. siRNA for experimental use can ... and then transfected into the target cells ...
... HybArray 12™ is an automated hybridization system ... system automates both the hybridization and post ... slides. A single instrument can process up ... pairs and has multi-protocol software, enabling the ...
... is commonly used as a fusion partner ... The GSTTag sequence has been reported to ... the solubility of its fusion partners. When ... GSTTag fusion proteins can be purified with ...
Biology Products: